HUTCHMED (China) Limited

Good day and thank you for standing by. Welcome to HutchMet 2023 Half-Year Financial Results presentation. At this time, all participants are in listen-only mode. After speaker's presentation, there will be question and answer session. To ask a question during this session, you will need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To record your question, please press star 1 1 again. Please be advised that today's conference is being recorded. And I'd like to hand the conference over to Mr. Mark Lee, Senior Vice President, Corporate Finance and Development of Hatchmat. Please go ahead, sir.

Thank you, Amber. Thank you, everybody, and welcome. At this time, I will remind you that the statements we have are forward-looking in nature, and the results and operations of the Hatchmat Group are historical, and past performance is no guarantee whatsoever. of future results and that this presentation is intended for investors only and should be read in conjunction with the announcement we just made regarding the results for the six months ended June 30th, 2023 and our various other filings and annual reports. Now I'll hand you over to Dr. Weiguo Su, our Chief Executive Officer and Chief Science Officer.

Thank you, Mark. Good evening. Good morning, everyone. Welcome to HMET first half 2023 results conference call. Next slide, please. During the first half of 2023, we focused on executing on our strategy for the long-term growth and also reaching profitability by 2025 goal, including China commercial growth and spending control. We also delivered on our key objectives with our pipeline. highlighted by frequenting the U.S. NDA and EU MAA submissions and advancement of multiple programs into pivotal registration studies, including salvalitinib second-line gastric and also HMPL453, our selective FGFR1, 2, and 3 inhibitor in second-line cholangiocarcinoma. Frequenting the U.S. NDA was granted priority reviews designation with a PDUFA date of November 30th, 2023. That means a potential approval before end of 2023. We are working with our partner Takeda closely to prepare for the launch in the U.S. China commercial of the three approved oncology products continues to grow in spite of the pandemic outbreak at the beginning of the year. Next slide. Today, I'm joined by the Hutchman Senior Management Team. Johnny Chan will lead off with a financial update. Johnny, over to you.